Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in San Antonio, Texas

This page shows live ClinicalTrials.gov search results for San Antonio, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
3153
Shown on this page
12
Current sort
Recently updated
Location scope
San Antonio, TX
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within San Antonio, Texas. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 205–216 of 3,153 matching trials in San Antonio, TX.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Recruiting Not applicable Interventional

Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury

NCT05758077
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Selective Cytopheretic Device, Standard of Care
Device · Other
Lead sponsor
SeaStar Medical
Industry
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 4, 2026, 5:12 AM EST
Active, not recruiting Phase 2 Interventional Results available

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

NCT03595124
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, TFE3-Rearranged Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
Interventions
Axitinib, Nivolumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
266
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 168 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 4, 2026, 5:12 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01896999
View directory record Official record
Conditions
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
479
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 303 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 4, 2026, 5:12 AM EST
Active, not recruiting Phase 2 Interventional

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

NCT07094516
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
VHB937, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
22
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 4, 2026, 5:12 AM EST
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT06004245
View directory record Official record
Conditions
Advanced Solid Tumors, Colorectal Cancer
Interventions
VVD-133214, Pembrolizumab, Bevacizumab
Drug
Lead sponsor
Vividion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
18
States / cities
Tucson, Arizona • Duarte, California • Irvine, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 4, 2026, 5:12 AM EST
Recruiting Phase 3 Interventional

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931
View directory record Official record
Conditions
Crohn's Disease
Interventions
Duvakitug, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years to 80 Years
Enrollment
980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
127
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 4, 2026, 5:12 AM EST
Recruiting Not applicable Interventional

EFS of the DUO System for Tricuspid Regurgitation

NCT05913908
View directory record Official record
Conditions
Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases
Interventions
DUO Transcatheter Tricuspid Coaptation Valve System
Device
Lead sponsor
CroiValve Limited
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
14
States / cities
Phoenix, Arizona • Thousand Oaks, California • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 4, 2026, 5:12 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)

NCT00608764
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Emphysema, Bronchitis, Chronic
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 80 Years
Enrollment
10,718 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 4, 2026, 5:12 AM EST
Recruiting No phase listed Observational

Quality of Pediatric Resuscitation in a Multicenter Collaborative

NCT02708134
View directory record Official record
Conditions
Cardiac Arrest, Cardiopulmonary Arrest
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 18 Years
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
42
States / cities
Los Angeles, California • Madera, California • Orange, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 4, 2026, 5:12 AM EST
Active, not recruiting Phase 3 Interventional Results available

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

NCT02112916
View directory record Official record
Conditions
Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma, Ann Arbor Stage III Childhood Lymphoblastic Lymphoma, Ann Arbor Stage IV Adult Lymphoblastic Lymphoma, Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma, Childhood T Acute Lymphoblastic Leukemia
Interventions
Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Radiation Therapy, Thioguanine, Vincristine, Vincristine Sulfate
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
188
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 143 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 4, 2026, 5:12 AM EST
Recruiting Phase 3 Interventional

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184944
View directory record Official record
Conditions
Crohn's Disease
Interventions
Duvakitug, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years to 80 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
34
States / cities
Colorado Springs, Colorado • Kissimmee, Florida • Miami, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 4, 2026, 5:12 AM EST
Recruiting Phase 3 Interventional

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

NCT07405164
View directory record Official record
Conditions
Von Hippel-Lindau Disease, Malignant Neoplasms
Interventions
Belzutifan, Nivolumab, Lenvatinib, Cabozantinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
8
States / cities
Boston, Massachusetts • Detroit, Michigan • Philadelphia, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 4, 2026, 5:12 AM EST